STOCK TITAN

NUS Rule 144 Notice: 23,391 Common Shares via Morgan Stanley

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filed for NuSkin Enterprises, Inc. (NUS) reports a proposed sale of 23,391 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $283,117.65. The filing lists the approximate date of sale as 08/29/2025 and shows 49,497,715 shares outstanding. All 23,391 shares were acquired as gifts from affiliate Daniel Campbell on 11/02/2021, with donor acquisition dates and per-lot amounts totaling the 23,391 shares. The filer reports "Nothing to Report" for securities sold in the past three months and includes the standard representation that no undisclosed material adverse information about the issuer is known.

Positive

  • Full lot-level acquisition details are provided, showing each donor acquisition date and lot size that sum to the 23,391 shares to be sold
  • Broker and proposed sale date disclosed: Morgan Stanley Smith Barney LLC and 08/29/2025 are specified
  • Aggregate market value stated as $283,117.65, giving clear dollar exposure for the proposed sale
  • No sales reported in the past three months, indicating this is not part of a recent selling pattern

Negative

  • None.

Insights

TL;DR: Routine Rule 144 notice for a small block of NUS common shares acquired by gift and proposed to be sold via Morgan Stanley.

The filing documents a proposed sale of 23,391 common shares of NuSkin (aggregate value $283,117.65) using Morgan Stanley Smith Barney LLC as broker, with the sale date listed as 08/29/2025. All shares were acquired as gifts from Daniel Campbell on 11/02/2021, and the schedule shows donor acquisition dates and lot sizes that sum to the total shares to be sold. There are no reported sales in the prior three months, indicating this filing is a standalone proposed sale rather than part of a recent selling pattern. From a market-impact perspective, the block represents roughly 0.047% of the reported 49,497,715 shares outstanding, suggesting limited potential market impact.

TL;DR: Disclosure appears complete for a Rule 144 notice: acquisition source, lot details, broker, and representation are provided.

The form provides required Rule 144 information: identity of broker, precise share count, aggregate market value, lot-level acquisition details showing gifts from an affiliate, and the usual attestation about undisclosed material information. The filing states no securities were sold in the prior three months and includes the standard legal warning about intentional misstatements. There is no additional governance-related information such as a trading plan date or signature block content disclosed in the provided text.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for NuSkin (NUS) report?

The notice reports a proposed sale of 23,391 common shares of NuSkin with an aggregate market value of $283,117.65 through Morgan Stanley Smith Barney LLC on 08/29/2025.

How were the 23,391 NuSkin shares acquired?

All 23,391 shares were acquired as gifts from affiliate Daniel Campbell on 11/02/2021, with donor acquisition dates and lot sizes listed in the filing.

Does the filing show any NuSkin securities sold in the last three months?

The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What broker is handling the proposed sale of NUS shares?

The broker named in the filing is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

How many NuSkin shares are outstanding according to the filing?

The filing shows 49,497,715 shares outstanding.
Nu Skin Enter

NYSE:NUS

NUS Rankings

NUS Latest News

NUS Latest SEC Filings

NUS Stock Data

402.95M
68.52M
Household & Personal Products
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
PROVO